Quote:

---

Find a 9 year old who believes that the world is a giant conspiracy to keep us all from succeeding - and they'll be happy to indulge you.

---

Really? Filing a BLA for 350mg in HIV would have been simple and straight forward no trying to kludge together two different studies with the nightmare that would produce. Then having to go back and do extra safety studies. Yet the FDA insisted on it. Receptor occupancy wasn't part of the trial and is unnecessary. The FDA insisted on that knowing we had only started that toward the end of the mono trial and had incomplete data. 700mg could have easily be done as an additional trial after approval at 350mg.

The FDA insisting on two doses knowing there would be incomplete drug coverage in a 4 week trial. When the company was asking for four doses that was intentional on the FDA's part.

If you don't think there's corruption in the FDA then you believe in fairytales.

It isn't all on the FDA but if it wasn't for their decisions Cytodyn would have HIV approval and a fairly good chance of having Covid approval.

When it comes to the share price it's a combination of factors -

Failed BLA submission (thanks FDA).
Failed mild/moderate Covid (thanks whomever set up the protocol and by extension Nader).
Failed severe/critical Covid (thanks FDA).
Self enrichment lawsuits (bad Nader).
Shareholder lawsuits (why did the attorney's file frivolous lawsuits with little opportunity of recompense?).
A shareholder proxy fight.
A small amount of opportune shorting.
Manipulation by market makers to do some scalping.
Trolls repetitiously slamming the company (how many times do we have to hear about 2 bullshit felonies).
PRs that project the best possible light on results rather than releasing full data (which is why we need data releases on longhaulers and cancer right now).